Trial Profile

A pivotal Phase III study of 64Cu-SAR-bombesin-Clarity-Pharmaceuticals in patients with prostate cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 25 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 64Cu SAR bombesin-Clarity Pharmaceuticals (Primary)
Indications Pancreatic cancer
Focus Registrational; Therapeutic Use

Most Recent Events

25 Jul 2023 New trial record
24 Jul 2023 According to a Clarity Pharmaceuticals Media Release, clarity is planning to launch a pivotal Phase III diagnostic trial for first product approval in the US.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com